Advanced Accelerator Applications (Novartis)
The CERN spin-out that Novartis bought in 2018 for Lutathera, which now makes Pluvicto and the Locametz and Netspot imaging kits.
Overview
Advanced Accelerator Applications, based in Saint-Genis-Pouilly, France, and founded in 2002, is the CERN spin-out that Novartis bought in 2018 for Lutathera, and it now makes Pluvicto and the Locametz and Netspot imaging kits. AAA developed Lutathera, or 177Lu-DOTATATE, and the Netspot gallium-68 DOTATATE kit before its 3.9 billion dollar acquisition, and as Novartis' radioligand unit it manufactures Locametz, the gallium-68 PSMA-11 kit, and Pluvicto and runs the Novartis radioligand production network in Europe and the United States. Nuclide links it to prostate cancer and neuroendocrine tumours, to PSMA PET, somatostatin receptor PET and beta-emitter radioligand therapy, and to Novartis. Whether its production network can meet demand as radioligand indications widen is the open question. Locametz and Pluvicto have their own pages.
Scorecard
All companies- approved products +18
- targets +4
- modalities +4
- regions +6
- 24-month regulatory events +4
- registry trials +13
Novartis' gallium PSMA scan kit, approved the same day as Pluvicto as the test that qualifies men for that radioactive drug.
The PET scan for neuroendocrine tumours that finds far more disease than older scans and confirms eligibility for lutetium radioligand therapy (the theranostic pair).
A radioactive drug that seeks out PSMA on prostate cancer cells; the best-selling radiopharmaceutical ever.
Similar pages
not linked directly; found by shared links- PersonJohannes Czernin
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Gallium-68, Radioligand therapy (beta emitters).
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Lutetium-177 vipivotide tetraxetan, Gallium-68, Prostate cancer.
- BottleneckSite readiness and referral pathway delays
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours.
- InstitutionIRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)
Shares Lutetium-177 vipivotide tetraxetan, Neuroendocrine tumours, PSMA PET, Radioligand therapy (beta emitters).
- PersonRahul Aggarwal
Shares Lutetium-177 vipivotide tetraxetan, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
- Pairing68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours, Gallium-68.
- TermKrenning score
Shares Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours, Gallium-68.
- TermTheranostics
Shares Locametz (kit for Ga-68 gozetotide), Gallium-68 DOTATATE (and Cu-64 DOTATATE), Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours.